Answers are grounded in this paper and cite their sources.
Blinded trial reports negligible effect on hand mobility, suggesting UVA1 may enhance health-related outcomes in systemic sclerosis.
Effective tools for improving sclerotic hand changes in patients with systemic sclerosis are lacking; thus, we conducted a single-blind, prospective, randomized clinical trial investigating the impact of UVA1 phototherapy on scleroderma of the hands. 8 patients were unilaterally treated, and we found no evidence of significant change in Hand Mobility in Scleroderma (HAMIS) scores after 30 treatments. However, patients did report significant health-related outcome changes in the emotional, symptomatic, and functional domains of Skindex-16 (β=−34.1 (95% CI −47.0, −21.3), −26.3 (−38.1, −14.4), and −13.1 (−20.9, −5.41), respectively).
No takes yet. Share an insight, caveat, or question.
Christiaan H Noot (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: